Abstract 5278
Background
We evaluated the impact of tumor type and molecular profiling on overall survival of patients (pts) with cancer referred to Medical Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).
Methods
Pts referred from 1989 to 2017 had molecular testing (for research) of archival tumor tissue collected at the time of diagnosis (stage I-III, 82%; stage IV, 18%). Tumor-specific (e.g. breast, colon) gene panels (45-101 genes) were used to identify pathogenic mutations in clinically relevant genes. Deep sequencing was performed at the Laboratory of Molecular Oncology, Aristotle University of Thessaloniki and HeCOG. Mutation annotation was performed at MD Anderson Cancer Center. All pts received standard-of-care anticancer therapy.
Results
We analyzed 3,211 pts (median age, 58 years; men, 29%) with informative sequencing data. Results by tumor type and molecular pathway are shown in the table. Overall, 1,193 (37%) pts had ≥1 actionable alterations [115 (3.6%) ≥4]. The most common affected pathways were PI3K, RAF/MEK, homologous recombination repair (HRR), and tyrosine kinase; 294 (9.2%) pts had alterations in > 1 pathways. The median follow-up of alive patients is 7.48 years (yrs) (95%CI, 7.36-7.59). Of 3,211 pts, 1,060 (33.01%) have died. The median overall survival is 16.08 yrs (95%CI, 13.25-16.75). Of pts with breast cancer and actionable mutations, the 5-yr survival rates were: stage I-III (n = 501) 88.8%; stage IV (n = 14), 51.1% (p<.0001). Of pts with colorectal cancer and actionable alterations, the 5-yr survival rates were: stage I-III (n = 299), 76.5%; stage IV (n = 50), 15.2% (p<.0001).
Conclusions
Tumor sequencing revealed clinically relevant genomic mutations in several molecular pathways. Prospective clinical trials validating the clinical utility of tumor profiling are warranted.
Clinical trial identification
Legal entity responsible for the study
Hellenic Cooperative Oncology Group.
Funding
Hellenic Cooperative Oncology Group.
Editorial Acknowledgement
NA
Disclosure
All authors have declared no conflicts of interest.Table: 1876P
| Total N | N with actionable alterations | % | Overall Survival | ||
|---|---|---|---|---|---|
| Tumor type | Median, Years (95% CI) | 5-yr OS, % (95% CI) | |||
| Breast | 1,964 | 527 | 27 | NR | 87.8 (85.0-90.7) |
| Colorectal | 533 | 359 | 67 | NR | 68.0 (63.2-73.2) |
| Pancreatic | 188 | 123 | 65 | 0.82 (.65-.98) | - |
| Nasopharyngeal | 144 | 77 | 54 | 8.92 (6.68-NR) | 65.2 (54.7-77.7) |
| Brain | 131 | 24 | 18 | 4.54 (1.69-9.71) | 46.9 (29.9-73.6) |
| Gastric | 101 | 11 | 11 | 4.18 (1.04-NR) | 39.8 (17.8-88.9) |
| Biliary Tract | 80 | 26 | 33 | ND | |
| Ovarian | 70 | 46 | 66 | 3.24 (2.18-5.32) | 36.4 (24.7-53.5) |
| Total | 3,211 | 1,193 | 37 | 13.23 (10.6-NR) | 68.6 (65.9-71.4) |
| Pathway | Total tested | N with actionable alterations | % | ||
| PI3K/AKT/mTOR | 3,211 | 636 | 20 | 16.08 (13.23- NR) | 82.3 (79.3-85.4) |
| MEK/RAF | 3,211 | 459 | 14 | 6.4 (4.08-8.92) | 52.3 (47.7-57.3) |
| HRR | 3,211 | 260 | 8 | 7.84 (5.33-NR) | 56.8 (50.7-63.5) |
| Tyrosine kinase | 3,211 | 161 | 5 | NR | 69.2 (62.0-77.3) |
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract